Merck Net Income From Continuing Ops vs Research Development Analysis

0QAH Stock

USD 103.50 27.80 21.17%

Merck financial indicator trend analysis is infinitely more than just investigating Merck Company recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Merck Company is a good investment. Please check the relationship between Merck Net Income From Continuing Ops and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Net Income From Continuing Ops vs Research Development

Net Income From Continuing Ops vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Merck Company Net Income From Continuing Ops account and Research Development. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Merck's Net Income From Continuing Ops and Research Development is -0.49. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Research Development in the same time period over historical financial statements of Merck Company, assuming nothing else is changed. The correlation between historical values of Merck's Net Income From Continuing Ops and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Merck Company are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Net Income From Continuing Ops i.e., Merck's Net Income From Continuing Ops and Research Development go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Net Income From Continuing Ops

Research Development

Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Merck's Tax Provision is quite stable compared to the past year. Selling General Administrative is expected to rise to about 10.8 B this year, although the value of Discontinued Operations will most likely fall to about 601.9 M.

	2020	2021	2023	2024 (projected)
EBIT	7.7B	13.9B	16.0B	11.8B
Discontinued Operations	2.5B	704M	633.6M	601.9M

Ebit Discontinued Operations

Merck fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Good Will	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab
Other Current Liab		0.91	-0.8	0.74	0.62	-0.07	0.81	0.59	0.17	0.96	0.23	0.66	-0.54	0.82	0.61	0.59	0.72	0.17	0.25	0.58	-0.53	0.64	0.59	0.31	0.47	0.32
Total Current Liabilities	0.91		-0.71	0.66	0.62	0.04	0.93	0.6	0.23	0.91	0.23	0.62	-0.67	0.73	0.67	0.58	0.67	0.28	0.23	0.67	-0.6	0.67	0.68	0.56	0.64	0.55
Other Liab	-0.8	-0.71		-0.99	-0.89	0.03	-0.6	-0.87	-0.6	-0.86	-0.6	-0.93	0.72	-0.95	-0.91	-0.89	-0.99	-0.16	-0.44	-0.87	0.82	-0.9	-0.88	-0.49	-0.7	-0.44
Net Tangible Assets	0.74	0.66	-0.99		0.9	-0.1	0.52	0.84	0.66	0.79	0.57	0.94	-0.76	0.89	0.91	0.89	0.98	0.1	0.52	0.86	-0.87	0.87	0.89	0.57	0.68	0.46
Retained Earnings	0.62	0.62	-0.89	0.9		0.29	0.6	0.94	0.45	0.69	0.8	0.99	-0.57	0.85	0.96	0.99	0.9	-0.15	0.72	0.92	-0.96	0.81	0.92	0.5	0.64	0.28
Accounts Payable	-0.07	0.04	0.03	-0.1	0.29		0.39	0.43	-0.4	0.05	0.7	0.17	0.37	0.18	0.24	0.35	0.03	-0.27	0.22	0.29	-0.19	0.14	0.23	-0.27	0.16	-0.28
Other Assets	0.81	0.93	-0.6	0.52	0.6	0.39		0.67	0.04	0.86	0.43	0.56	-0.46	0.72	0.64	0.6	0.59	0.24	0.17	0.67	-0.53	0.66	0.66	0.36	0.65	0.42
Net Receivables	0.59	0.6	-0.87	0.84	0.94	0.43	0.67		0.47	0.74	0.89	0.91	-0.54	0.91	0.96	0.97	0.91	0.09	0.46	0.96	-0.85	0.92	0.94	0.39	0.79	0.37
Inventory	0.17	0.23	-0.6	0.66	0.45	-0.4	0.04	0.47		0.33	0.25	0.49	-0.85	0.46	0.61	0.45	0.67	0.54	0.02	0.63	-0.52	0.7	0.65	0.7	0.73	0.78
Other Current Assets	0.96	0.91	-0.86	0.79	0.69	0.05	0.86	0.74	0.33		0.41	0.71	-0.63	0.92	0.74	0.69	0.83	0.34	0.16	0.74	-0.59	0.82	0.73	0.37	0.68	0.47
Other Stockholder Equity	0.23	0.23	-0.6	0.57	0.8	0.7	0.43	0.89	0.25	0.41		0.74	-0.17	0.69	0.78	0.86	0.67	-0.14	0.48	0.78	-0.68	0.69	0.74	0.09	0.56	0.04
Total Current Assets	0.66	0.62	-0.93	0.94	0.99	0.17	0.56	0.91	0.49	0.71	0.74		-0.6	0.86	0.95	0.98	0.92	-0.15	0.72	0.89	-0.95	0.81	0.91	0.51	0.61	0.28
Common Stock	-0.54	-0.67	0.72	-0.76	-0.57	0.37	-0.46	-0.54	-0.85	-0.63	-0.17	-0.6		-0.59	-0.72	-0.54	-0.75	-0.54	-0.12	-0.73	0.66	-0.77	-0.77	-0.89	-0.83	-0.91
Property Plant Equipment	0.82	0.73	-0.95	0.89	0.85	0.18	0.72	0.91	0.46	0.92	0.69	0.86	-0.59		0.88	0.87	0.95	0.23	0.31	0.87	-0.72	0.92	0.85	0.31	0.72	0.38
Total Assets	0.61	0.67	-0.91	0.91	0.96	0.24	0.64	0.96	0.61	0.74	0.78	0.95	-0.72	0.88		0.97	0.95	0.11	0.53	0.99	-0.94	0.93	0.99	0.61	0.83	0.51
Total Stockholder Equity	0.59	0.58	-0.89	0.89	0.99	0.35	0.6	0.97	0.45	0.69	0.86	0.98	-0.54	0.87	0.97		0.91	-0.1	0.66	0.93	-0.93	0.85	0.93	0.44	0.68	0.28
Property Plant And Equipment Net	0.72	0.67	-0.99	0.98	0.9	0.03	0.59	0.91	0.67	0.83	0.67	0.92	-0.75	0.95	0.95	0.91		0.22	0.4	0.93	-0.84	0.95	0.93	0.52	0.78	0.51
Net Debt	0.17	0.28	-0.16	0.1	-0.15	-0.27	0.24	0.09	0.54	0.34	-0.14	-0.15	-0.54	0.23	0.11	-0.1	0.22		-0.75	0.22	0.16	0.44	0.2	0.27	0.61	0.77
Cash	0.25	0.23	-0.44	0.52	0.72	0.22	0.17	0.46	0.02	0.16	0.48	0.72	-0.12	0.31	0.53	0.66	0.4	-0.75		0.42	-0.77	0.19	0.46	0.32	0.02	-0.21
Non Current Assets Total	0.58	0.67	-0.87	0.86	0.92	0.29	0.67	0.96	0.63	0.74	0.78	0.89	-0.73	0.87	0.99	0.93	0.93	0.22	0.42		-0.89	0.95	1.0	0.61	0.89	0.58
Non Currrent Assets Other	-0.53	-0.6	0.82	-0.87	-0.96	-0.19	-0.53	-0.85	-0.52	-0.59	-0.68	-0.95	0.66	-0.72	-0.94	-0.93	-0.84	0.16	-0.77	-0.89		-0.75	-0.92	-0.69	-0.65	-0.39
Long Term Debt	0.64	0.67	-0.9	0.87	0.81	0.14	0.66	0.92	0.7	0.82	0.69	0.81	-0.77	0.92	0.93	0.85	0.95	0.44	0.19	0.95	-0.75		0.94	0.53	0.92	0.65
Good Will	0.59	0.68	-0.88	0.89	0.92	0.23	0.66	0.94	0.65	0.73	0.74	0.91	-0.77	0.85	0.99	0.93	0.93	0.2	0.46	1.0	-0.92	0.94		0.68	0.88	0.61
Common Stock Shares Outstanding	0.31	0.56	-0.49	0.57	0.5	-0.27	0.36	0.39	0.7	0.37	0.09	0.51	-0.89	0.31	0.61	0.44	0.52	0.27	0.32	0.61	-0.69	0.53	0.68		0.67	0.82
Non Current Liabilities Total	0.47	0.64	-0.7	0.68	0.64	0.16	0.65	0.79	0.73	0.68	0.56	0.61	-0.83	0.72	0.83	0.68	0.78	0.61	0.02	0.89	-0.65	0.92	0.88	0.67		0.84
Total Liab	0.32	0.55	-0.44	0.46	0.28	-0.28	0.42	0.37	0.78	0.47	0.04	0.28	-0.91	0.38	0.51	0.28	0.51	0.77	-0.21	0.58	-0.39	0.65	0.61	0.82	0.84

Click cells to compare fundamentals

Merck Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Net Income From Continuing Ops vs Research Development Analysis

Net Income From Continuing Ops vs Research Development

Net Income From Continuing Ops vs Research Development Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Research Development

Merck fundamental ratios Correlations

Merck Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Non Current Assets Total
Total Current Assets	+ 0.99	Retained Earnings
Total Stockholder Equity	+ 0.99	Retained Earnings
Non Current Assets Total	+ 0.99	Total Assets
Good Will	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.98	Net Tangible Assets

Property Plant And Equipment Net	- 0.99	Other Liab
Net Tangible Assets	- 0.99	Other Liab
Non Currrent Assets Other	- 0.96	Retained Earnings
Non Currrent Assets Other	- 0.95	Total Current Assets
Property Plant Equipment	- 0.95	Other Liab
Non Currrent Assets Other	- 0.94	Total Assets